Close Menu

NEW YORK (GenomeWeb) – Cowen has initiated coverage on Horizon Discovery Group with an Outperform rating and a £2.90 ($3.73) price target.

In a research note, Cowen's Doug Schenkel noted that Horizon has "quickly evolved into an emerging leader in gene editing life science tools," especially in the wake of the company's July acquisition of Dharmacon from GE.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.

US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.

The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.

In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.